PHARMX TECHNOLOGIES LIMITED — Capital/Financing Update 2026

Feb 22, 2026

ASX Announcement

23 February 2026

Pharmx and Sigma enter multi-year strategic alliance

Sydney, 23 February 2026: Pharmx Technologies Limited (ASX: PHX), (Pharmx) is pleased to announce it has entered into a binding, multi-year strategic alliance with Sigma Healthcare Limited (ASX: SIG), (Sigma) one of Australia's leading pharmaceutical wholesalers and retail pharmacy operators.

The new alliance positions Pharmx as a core technology infrastructure partner to Sigma and the Chemist Warehouse network. Sigma currently services over 3,000 pharmacy customers in Australia including 850 Chemist Warehouse, Amcal and Discount Drug Stores franchises, and over 90 stores across the Republic of Ireland, UAE and New Zealand.

As part of the agreement, Pharmx becomes the preferred EDI (Electronic Data Interchange) service provider for Sigma wholesale, and Chemist Warehouse retail operations across Australia and New Zealand.

Furthermore, the parties will collaborate on global EDI capabilities and a range of other digital services designed to modernise pharmacy supply chains and support industry-wide efficiency and growth.

Pharmx will continue to operate as an independent, whole-of-market solutions provider for the ANZ pharmacy sector, working across all major wholesalers, suppliers, vendors and pharmacies.

The strategic alliance initiatives will be delivered in two parts.

• Under Part A of the agreement Pharmx becomes the preferred EDI partner for Sigma wholesale and the Chemist Warehouse retail operations across Australia and New Zealand and will directly support Sigma’s growth in the NZ market. Sigma will renew its existing agreements for the provision of EDI services for its wholesale business for a further 5 years. Sigma will subscribe for approximately 59.95 million Pharmx shares (10% of Pharmx’s issued share capital) and will obtain a seat on the Pharmx Board, reinforcing the strategic alignment.

• Under Part B , Pharmx will expand the scope of services available to Sigma across additional international markets and new solution areas. Sigma will have the opportunity to subscribe for further Pharmx shares up to an aggregate holding of 19.9% over the term of the alliance, with any such additional issues priced at the 30-day volume weighted average price prior to the relevant issue and subject to Pharmx shareholder approval to the extent required. Any shares issued to Sigma under the alliance will be subject to a three-year escrow period.

In return for entering into the strategic alliance, and the long-term commitment to procure services, Pharmx will pay Sigma an establishment fee of approximately $8.7 million.

PO BOX Q1222 info@pharmx.com.au Queen Victoria Building www.pharmx.com.au Sydney, NSW 1230 ABN: 25 000 091 305 1300 724 579 ACN: 000 091 305

The strategic alliance agreement is subject to standard termination provisions. While it is anticipated that the strategic alliance has the potential to increase revenues across Pharmx's Gateway, Marketplace and Analytics, as well as other opportunities, the incremental financial impact is not quantifiable until future statements of works have been defined and agreed by both parties.

Commenting on the strategic alliance, Pharmx CEO Tom Culver said:

“This partnership represents one of the most strategically significant milestones in Pharmx’s history.

Sigma’s decision to deepen its relationship with Pharmx during a period of major transformation following its merger with Chemist Warehouse, signals strong confidence in our technology, our strategy, and our execution.

The agreement has the potential to broaden our revenue profile, expand our footprint across ANZ, and establish a foundation for future global expansion. These opportunities result from the investments we have made in strengthening the Gateway, launching Marketplace, and accelerating our analytics strategy.

We look forward to partnering closely with Sigma to drive mutual growth and long-term value for Pharmx shareholders.”

Sigma CEO, Vikesh Ramsunder, commented:

“We are pleased to formalise this long-term partnership with Pharmx. The progress of Pharmx’s product suite and the alignment of our growth objectives make this a compelling strategic fit. By investing in Pharmx, we move beyond a traditional vendor-customer relationship to a scalable partnership that reduces complexity, enhances supply chain performance, drives deeper data analytics insights, and creates value and growth opportunities for both organisations.”

Part A of the expanded partnership will commence on 23 February 2026, with deliverables under this phase of the agreement to begin shortly thereafter.

Pharmx will be holding an investor briefing at 2pm on Monday 23 February 2026 to discuss the strategic alliance. Please register to attend at the following link:

• Investor Briefing: Strategic Alliance with Sigma Healthcare | Meeting Join | Microsoft Teams

Should you have any questions, we encourage shareholders to send through questions via email to the company at investor.relations@pharmx.com.au.

ENDS

This announcement has been authorised for lodgement by the Chairman.

For further information contact:

Tom Culver Chief Executive Officer investor.relations@pharmx.com.au

PO BOX Q1222 info@pharmx.com.au Queen Victoria Building www.pharmx.com.au Sydney, NSW 1230 ABN: 25 000 091 305 1300 724 579 ACN: 000 091 305

About Pharmx Technologies Ltd.

Pharmx is ANZ’s leading pharmacy ordering platform, providing important technology infrastructure for seamless ordering and inventory management. By connecting the largest network of pharmacies, suppliers, and technology vendors, Pharmx facilitates approximately $20 billion in transactions annually through its robust, high-availability platform, driving efficient operations, seamless connectivity, and valuable insights across its ordering, eInvoicing, and analytics solutions.

Operating in a dynamic and evolving market, Pharmx is positioned for sustained growth, driven by population growth, demographic shifts, and regulatory changes. With a strategic focus on expanding its addressable market, Pharmx leverages its extensive network, proprietary pharma-tech, and advanced data capabilities to unlock new revenue opportunities and enhance healthcare outcomes across Australia and New Zealand.

PO BOX Q1222 info@pharmx.com.au Queen Victoria Building www.pharmx.com.au Sydney, NSW 1230 ABN: 25 000 091 305 1300 724 579 ACN: 000 091 305